Investor Update

Basel, 07 July 2017

Invitation to Roche Analyst Event at ISTH 2017

Monday, 10 July 2017, 6:30pm CEST

Roche will host an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017.

Meeting Information


Monday, 10 July 2017


6:00pm Registration desk opens

6:30pm Start of meeting

7:45pm End of meeting followed by a buffet reception


Hotel Berlin, Berlin
Lützowplatz 17
10785 Berlin


HAVEN1: Ph3 data of emicizumab (ACE910) prophylaxis in adults with hemophilia A with inhibitors
Prof. Dr. med. Johannes Oldenburg, University Clinic Bonn, Institute of Experimental Hematology and Transfusion Medicine
HAVEN2: Ph3 interim data of emicizumab (ACE910) prophylaxis in pediatrics with hemophilia A with inhibitors; aspects of disease management
Gallia Levy, M.D., Medical Director Hematology
Emicizumab global development program
Cristin Hubbard, Lifecycle Leader emicizumab
Daniel O’Day, CEO Roche Pharmaceuticals

Dial in to the conference 10-15 minutes prior to the scheduled start, using the following dial-in numbers (listen-only mode, no live-access to speakers):

+41 (0) 58 310 5000 (Europe and ROW) or
+44 (0) 203 059 5862 (UK) or
+1 (1) 631 570 5613 (USA)

Alternatively a live audio webcast can be accessed via The presentation slides will be available from the IR website at following to the closure of the ISTH meeting.

A replay of the webcast will be available on demand on the Roche website.

Best regards,

Karl Mahler
Head of Investor Relations

Sabine Borngräber
Investor Relations Officer